Prurigo nodularis (PN) is challenging to treat, but new treatments show promise. Let’s look at symptoms and lots of ways to manage PN.

Prurigo nodularis is an extremely itchy skin condition. It causes a rash that often includes hard lumps called nodules. You might also hear it called nodular prurigo. Doctors don’t know exactly ...

The global prurigo nodularis market is surging due to rising prevalence, increased awareness, and treatment innovations. Key drivers include advanced biologic therapies like dupilumab, addressing ...

Randomized Phase 2 study met its primary and secondary endpoints following 16 weeks of treatment across all dosing groups, reinforcing povorcitinib’s potential role in treating prurigo nodularis ...

Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 ...

The FDA has approved dupilumab (Dupixent) as the first treatment with an indication for prurigo nodularis, Sanofi and Regeneron announced.. A chronic inflammatory skin condition affecting about ...

Sanofi and Regeneron's Dupixent has become the first biologic drug to show activity in prurigo nodularis (PN), raising the hope of a new treatment option for the rare and highly debilitating skin ...

The encouraging long-term efficacy and safety associated with nemolizumab (IL-31 inhibitor) in prurigo nodularis was supported by a second set of data showing long-term benefit in atopic dermatitis.

The first and only treatment for the disabling skin condition prurigo nodularis has been approved by the Food and Drug Administration in a development a D.C. dermatologist calls “huge.” ...

Galderma’s nemolizumab has been shown to improve the core signs and symptoms of prurigo nodularis, according to phase 3 results published in JAMA Dermatology. The 24-week OLYMPIA 1 trial evaluated the ...

Predictors of perceived stress, perceived stigmatization, and body dysmorphia in patients with chronic prurigo/prurigo nodularis: Results from an observational cross-sectional multicenter European ...

The approval stipulates use in adults with prurigo nodularis, a skin condition characterized by chronic itch, nodules covering large areas of the body, and poor sleep quality. Driven by IL-31 ...